Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial

BACKGROUND: Diarrhea-predominant irritable bowel syndrome (IBS-D) impairs patient quality of life (QOL). Rifaximin is an oral, nonsystemic antibiotic indicated for IBS-D. The objective of this secondary analysis was to evaluate rifaximin retreatment on IBS-related QOL in patients with IBS-D. METHODS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Therap Adv Gastroenterol
Main Authors: Cash, Brooks D., Pimentel, Mark, Rao, Satish S. C., Weinstock, Leonard, Chang, Lin, Heimanson, Zeev, Lembo, Anthony
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5598815/
https://ncbi.nlm.nih.gov/pubmed/28932270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X17726087
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados